Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Autoimmune Diseases Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Immunology Center for Excellence, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Immunobiology. 2023 May;228(3):152378. doi: 10.1016/j.imbio.2023.152378. Epub 2023 Mar 24.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the world causing a pandemic known as coronavirus disease 2019 (COVID-19). Cytokine storm was directly correlated with severity of COVID-19 syndromes. We evaluated the levels of 13 cytokines in ICU hospitalized COVID-19 patients (n = 29) before, and after treatment with Remdesivir as well as in healthy controls (n = 29). Blood samples were obtained from ICU patients during ICU admission (before treatment) and 5 days after treatment with Remdesivir. A group of 29 age- and gender-matched healthy controls was also studied. Cytokine levels were evaluated by multiplex immunoassay method using a fluorescence labeled cytokine panel. In comparison to cytokine levels measured at ICU admission, serum levels were reduced of IL-6 (134.75 pg/mL vs. 20.73 pg/mL, P < 0.0001), TNF-α (121.67 pg/mL vs. 10.15 pg/mL, P < 0.0001) and IFN-γ (29.69 pg/mL vs. 22.27 pg/mL, P = 0.005), whereas serum level was increased of IL-4 (8.47 pg/mL vs. 12.44 pg/mL, P = 0.002) within 5 days after Remdesivir treatment. Comparing with before treatment, Remdesivir significantly reduced the levels of inflammatory (258.98 pg/mL vs. 37.43 pg/mL, P < 0.0001), Th1-type (31.24 pg/mL vs. 24.46 pg/mL, P = 0.007), and Th17-type (36.79 pg/mL vs. 26.22 pg/mL, P < 0.0001) cytokines in critical COVID-19 patients. However, after Remdesivir treatment, the concentrations of Th2-type cytokines were significantly higher than before treatment (52.69 pg/mL vs. 37.09 pg/mL, P < 0.0001). In conclusion, Remdesivir led to decrease levels of Th1-type and Th17-type cytokines and increase Th2-type cytokines in critical COVID-19 patients 5 days after treatment.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在全球迅速传播，导致了一种被称为 2019 年冠状病毒病（COVID-19）的大流行。细胞因子风暴与 COVID-19 综合征的严重程度直接相关。我们评估了 29 例 ICU 住院 COVID-19 患者（n=29）在接受瑞德西韦治疗前后以及 29 例健康对照者（n=29）的 13 种细胞因子水平。在 ICU 入院时（治疗前）和接受瑞德西韦治疗 5 天后从 ICU 患者中采集血样。还研究了一组 29 名年龄和性别匹配的健康对照者。通过使用荧光标记细胞因子面板的多重免疫测定法评估细胞因子水平。与 ICU 入院时测量的细胞因子水平相比，血清中 IL-6（134.75pg/mL 比 20.73pg/mL，P<0.0001）、TNF-α（121.67pg/mL 比 10.15pg/mL，P<0.0001）和 IFN-γ（29.69pg/mL 比 22.27pg/mL，P=0.005）的水平降低，而 IL-4（8.47pg/mL 比 12.44pg/mL，P=0.002）的血清水平在接受瑞德西韦治疗 5 天后增加。与治疗前相比，瑞德西韦显著降低了炎症（258.98pg/mL 比 37.43pg/mL，P<0.0001）、Th1 型（31.24pg/mL 比 24.46pg/mL，P=0.007）和 Th17 型（36.79pg/mL 比 26.22pg/mL，P<0.0001）细胞因子的水平在重症 COVID-19 患者中。然而，在接受瑞德西韦治疗后，Th2 型细胞因子的浓度明显高于治疗前（52.69pg/mL 比 37.09pg/mL，P<0.0001）。总之，瑞德西韦在 COVID-19 重症患者接受治疗 5 天后导致 Th1 型和 Th17 型细胞因子水平降低，Th2 型细胞因子水平升高。
